Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Sony Group Corp (SONY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Sony Group Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.82 (market cap $4.49B), while Sony Group Corp trades at $21.17 (market cap $127.11B). The key difference: Sony Group Corp is far larger — about 28.3× ACADIA Pharmaceuticals Inc.'s market cap, and Sony Group Corp pays a 0.74% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SONY | |
|---|---|---|
Market Cap | $4.49B | $127.11B |
Sector | Health | Technology |
52-Week High | $28.06 | $30.26 |
52-Week Low | $20.06 | $19.32 |
Enterprise Value | $3.69B | $123.60B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Sony's stock trades at $21.40, up 2.93% today, with a bullish technical signal from moving averages. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. The company reported strong 2025 revenue of $12.96 trillion and net income of $1.14 trillion, though 2026 projections indicate a net loss. Analyst sentiment is positive, with 68.75% recommending buy. Recent news highlights Sony's shift to digital-only game discs by 2028, sparking consumer backlash.
The outlook is cautiously optimistic due to strong analyst support and solid cash flow, but risks include the negative profit margin forecast for 2026 and market reaction to the digital transition. Investors should weigh the company's innovation efforts against execution risks in a competitive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
